NRx Pharmaceuticals
Mr. Flynn is a founding investor in NRx. He is an entrepreneur with more than 30 years of senior executive experience. He has provided leadership to numerous successful organizations and has served in a variety of roles, including CEO, COO, CFO and advisor. Pat currently serves as COO of Good Measures, Inc. He co-founded Predilytics, Inc., which was sold to Welltock, Inc. Previously, Pat served as COO and then as CEO of Health Dialog, which was sold to BUPA International. Pat continued with BUPA, opening their business in the GCC and China. Mr. Flynn began his career with Bank of America where he held several positions over the course of 15 years, including Vice President of World Banking and Vice President of Risk Management.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
NRx Pharmaceuticals
NRx is a clinical-stage pharmaceutical company that is developing ZYESAMI (aviptadil acetate) for COVID-19 and NRX-101, the first oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder.